Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677353 | 0.88 | MEN1 (0.41) | KMT2AMAPTMEN1HTTPOLB | |
| SCHEMBL8775921 | 0.80 | MAPT (0.45) | BACE1KMT2AMAPTMEN1HTT | |
| SCHEMBL20088738 | 0.79 | MEN1 (0.54) | KMT2AMEN1HTTTDP1POLB | |
| SCHEMBL17876423 | 0.79 | KMT2A (0.49) | BACE1KMT2AMAPTTHRBPOLB | |
| SCHEMBL13677252 | 0.78 | KMT2A (0.51) | BACE1KMT2AMAPTHTTTDP1 | |
| SCHEMBL3987798 | 0.78 | MAPT (0.43) | BACE1KMT2AMAPTMEN1HTT | |
| SCHEMBL7721500 | 0.77 | POLB (0.63) | KMT2AMAPTMEN1POLB | |
| SCHEMBL13676924 | 0.75 | MAPT (0.41) | BACE1KMT2AMAPTMEN1HTT | |
| SCHEMBL7100111 | 0.75 | BACE1 (0.43) | BACE1KMT2AMEN1TDP1 | |
| SCHEMBL3994088 | 0.74 | KDM4E (0.41) | BACE1KMT2AMAPTMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | BACE1 592/4885KMT2A 3692/4885MAPT 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.